Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2858 - Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-4

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Guy Jerusalem

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

G. Jerusalem1, P.A. Fasching2, M. Martín3, X. Pivot4, K. Petrakova5, G.V. Bianchi6, A. Nusch7, G.S. Sonke8, L. De La Cruz Merino9, E. Vagnon10, J. Alam11, O. Kong11, D. Chandiwana11, M. De Laurentiis12

Author affiliations

  • 1 Medical Oncology, CHU Liege and Liege University, 4000 - Liège/BE
  • 2 Department Of Obstetrics And Gynecology, University Hospital Erlangen, 91054 - Erlangen/DE
  • 3 Instituto De Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam,, Universidad Complutense de Madrid, 28029 - Madrid/ES
  • 4 Department Of Medical Oncology, Institut Régional du Cancer, Strasbourg/FR
  • 5 Medical Oncology, Masaryk Memorial Cancer Institute, 65653 - Brno/CZ
  • 6 Oncologia Medica, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 7 Haematology And Internal Oncology, Onkologische Praxis Velbert, 42551 - Velbert/DE
  • 8 Medical Oncology, Netherlands Cancer Institute/BOOG Study Center, 1066 CX - Amsterdam/NL
  • 9 Clinical Oncology, Hospital Universitario Virgen Macarena, 41003 - Seville/ES
  • 10 Oncology, Novartis Pharma AG, CH 4002 - Basel/CH
  • 11 Oncology, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 12 Senology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
More

Resources

Abstract 2858

Background

RIB + FUL prolonged PFS vs placebo (PBO) + FUL in postmenopausal patients (pts) with HR+, HER2– ABC in the Phase 3 MONALEESA-3 study (NCT02422615). Consistent PFS benefit was observed in pts receiving treatment in either the first- (1L) or combined second-line (2L)/early relapse settings. Here we present additional efficacy and pain reduction results from MONALEESA-3.

Methods

Pts who received no or ≤ 1 line of prior endocrine therapy for ABC (i.e. receiving treatment in the 1L or 2L/early relapse settings, respectively) received RIB + FUL (n = 484) or PBO + FUL (n = 242). Endpoints included, primary: local PFS; secondary: overall response rate and health-related quality of life (HRQoL).

Results

As of Nov 3, 2017, median PFS was prolonged for RIB vs PBO in the separate 2L and early relapse settings (Table). Amongst the full population, 155/379 pts with measurable disease at baseline (41%; 95% CI 35.9–45.8) in the RIB arm and 52/181 (29%; 95% CI 22.1–35.3) in the PBO arm had a complete or partial response (P=0.003). The probability of a response by 6 months (RIB vs PBO arm) was 27% (95% CI 22.7–31.0) vs 16% (95% CI 12.0–21.6). At Week 8, a decrease from baseline in target lesion(s) size per RECIST was observed in (RIB vs PBO) 232/484 (48%) vs 92/242 (38%; P=0.006). A decrease in best % change from baseline in target lesion(s) size per RECIST was reported in 79% of 344 pts in the RIB arm and 66% of 166 pts in the PBO arm. At Cycle 3 Day 1 (Week 8), the absolute mean change from baseline in EORTC QLQ-C30 pain score was similar in both arms: –4.2 RIB (n = 361); –2.9 PBO (n = 169; P=0.517).Table: 331P

2L settingEarly relapse setting

Relapse >12 months from (neo)adjuvant endocrine therapy and subsequent progression on endocrine therapy for ABC

ABC at diagnosis that progressed after 1 line of endocrine therapy for ABC

Relapse on or ≤ 12 months after (neo)adjuvant endocrine therapy with no treatment for ABC
RIB + FULPBO + FULRIB + FULPBO + FUL
Pts, n993813771
Median PFS, months18.811.413.18.6
Hazard ratio (95% CI)0.539 (0.333–0.873)0.591 (0.422–0.830)

Conclusions

RIB + FUL consistently prolonged PFS in the separate 2L and early relapse settings. In the full population, RIB + FUL demonstrated early tumor size reduction and a higher response rate vs PBO + FUL, consistent with other RIB studies. Pain reduction was similar in both arms, suggesting addition of RIB to FUL does not negatively affect HRQoL.

Clinical trial identification

NCT02422615 April 21, 2015.

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.

Funding

Novartis Pharmaceuticals Corporation.

Editorial Acknowledgement

Editorial assistance was provided by Cassandra Krone PhD of ArticulateScience Ltd.

Disclosure

G. Jerusalem: Grants and personal fees: Novartis, during the conduct of the study; Grants, personal fees and non-financial support: Novartis, Roche; Personal fees and non-financial support: Lilly, Celgene, BMS; Grants and personal fees: Amgen; Personal fees: Pfizer, Puma, Daiichi-Sankyo; Grants from MSD; Personal fees and non-financial support: AstraZeneca, outside the submitted work. P.A. Fasching: Grants and personal fees: Novartis; Personal fees: Roche, Pfizer, Celgene, Teva, during the conduct of the study. M. Martín: Consulting/advisory role and research funding: Novartis, Roche/Genentech; Consulting/advisory role funding: Lilly; Consulting/advisory role funding: Pfizer, during the conduct of the study. K. Petrakova: Consulting/advisory role, Speaker's bureau, Travel/accommodation/expenses: Roche, Pfizer, Novartis, during the conduct of the study. G.S. Sonke: Institutional reimbursement for patient accrual: Novartis, during the conduct of the study; Institutional reimbursement for education and steering committee activities: Novartis; Institutional research support: Merck, AstraZeneca, Roche, outside the submitted work. E. Vagnon, J. Alam: Employment with Novartis. O. Kong, D. Chandiwana: Employment and stock ownership: Novartis. M. De Laurentiis: Grants and personal fees: Novartis, during the conduct of the study; Grants and personal fees: Pfizer, Roche, Astra Zeneca, Amgen; Grants: MSD, outside the submitted work.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.